论文部分内容阅读
目的观察孟鲁司特联合沙美特罗加氟替卡松联合治疗儿童中重度支气管哮喘的临床效果。方法选择2013年3月-2014年4月来医院就诊的重度支气管哮喘患者78例,根据治疗方法的不同,将所有患者按随机抽样的方法分为试验组和对照组各39例,对照组采用沙美特罗加氟替卡松吸入剂经口吸入。试验组应用沙美特罗加氟替卡松吸入剂的同时,口服孟鲁司特咀嚼片待症状控制后维持原剂量服用1个月,观察2组疗效。记录所有治疗前后肺功能的改变情况,包括第一秒用力呼气量(FEV1%)和最大呼气流量(PEF)以及测定血清Ig E、呼气一氧化氮(FeNO)。结果治疗后,试验组FEV1%和PEF的改变较对照组改善明显(P<0.05),试验组血清Ig E、Fe NO较对照组降低显著(P<0.05)。结论孟鲁司特和沙美特罗加氟替卡松联合治疗中重度支气管哮喘疗效显著,值得临床推广应用。
Objective To observe the clinical efficacy of montelukast combined with salmeterol and fluticasone in the treatment of children with moderate and severe bronchial asthma. Methods Seventy-eight patients with severe bronchial asthma who visited the hospital from March 2013 to April 2014 were divided into experimental group and control group (39 cases) according to the different treatment methods. All patients were randomly divided into experimental group and control group Salmeterol plus fluticasone inhalant inhaled orally. Test group Salmeterol plus fluticasone inhalation while oral montelukast chewable tablets to control the symptoms to maintain the original dose of 1 month to observe the 2 groups. All changes in lung function before and after treatment were recorded, including forced expiratory volume in one second (FEV1%) and maximum expiratory flow (PEF), and serum Ig E and exhaled nitric oxide (FeNO). Results After treatment, the changes of FEV1% and PEF in experimental group were significantly improved compared with those in control group (P <0.05). The levels of serum Ig E and Fe NO in experimental group were significantly lower than those in control group (P <0.05). Conclusion Montelukast and salmeterol plus fluticasone combined treatment of moderate and severe bronchial asthma significant effect, worthy of clinical application.